Mylan Inc. (MYL) Gains Buy Rating at Argus

Mylan Inc. (MYL) has been upgraded today by the research analysts at investment firm Argus which adjusted MYL  from a “hold” rating to “buy.”  Argus also set a price target for MYL at $29 dollars.  MYL is up during intraday trading.

Mylan is slated to release their next earnings report on July 28th, 2011  and is estimated to post EPS of 45 cents.  Their last earnings report was released on May 3rd, 2011 and announced EPS of 44 cents with revenue totaling 1.436 billion which was up 12.4 % year to year.  MYL is currently trading above its 50 & 200-day moving averages and 2011 is an up year for the company.

Mylan Inc. maintains one of the industry’s broadest product portfolios supported by a robust product pipeline and a vertically integrated active pharmaceutical ingredient operation and runs a specialty business focused on respiratory, allergy and psychiatric therapies.  The company has market capitalization of $10,227,000,000 and 437,057,000 shares outstanding.  MYL has a 52-week high of $25.46 with the low being $16.55 dollars.



Latest News

HFF  Sees Unusually-High Trading Volume
HFF Sees Unusually-High Trading Volume
ValueChain  Achieves Market Cap of $0.00
ValueChain Achieves Market Cap of $0.00
GuccioneCoin Price Reaches $0.0012 on Top Exchanges
GuccioneCoin Price Reaches $0.0012 on Top Exchanges
Metaverse ETP Price Reaches $0.68
Metaverse ETP Price Reaches $0.68
Teva Pharmaceutical Industries  Bond Prices Fall 1.3%
Teva Pharmaceutical Industries Bond Prices Fall 1.3%
Corus Entertainment  Stock Price Up 3.1%
Corus Entertainment Stock Price Up 3.1%


© 2006-2019 Ticker Report